Logo image of LEXX

LEXARIA BIOSCIENCE CORP (LEXX) Stock Fundamental Analysis

NASDAQ:LEXX - Nasdaq - US52886N4060 - Common Stock - Currency: USD

1.45  +0.02 (+1.4%)

After market: 1.4512 +0 (+0.08%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to LEXX. LEXX was compared to 194 industry peers in the Pharmaceuticals industry. While LEXX has a great health rating, there are worries on its profitability. LEXX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year LEXX has reported negative net income.
LEXX had a negative operating cash flow in the past year.
In the past 5 years LEXX always reported negative net income.
LEXX had a negative operating cash flow in each of the past 5 years.
LEXX Yearly Net Income VS EBIT VS OCF VS FCFLEXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

With a Return On Assets value of -74.74%, LEXX is not doing good in the industry: 72.97% of the companies in the same industry are doing better.
The Return On Equity of LEXX (-74.89%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -74.74%
ROE -74.89%
ROIC N/A
ROA(3y)-124.81%
ROA(5y)-108.73%
ROE(3y)-127.55%
ROE(5y)-113.67%
ROIC(3y)N/A
ROIC(5y)N/A
LEXX Yearly ROA, ROE, ROICLEXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

With an excellent Gross Margin value of 99.45%, LEXX belongs to the best of the industry, outperforming 98.92% of the companies in the same industry.
In the last couple of years the Gross Margin of LEXX has grown nicely.
The Profit Margin and Operating Margin are not available for LEXX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.01%
GM growth 5Y1.71%
LEXX Yearly Profit, Operating, Gross MarginsLEXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

8

2. Health

2.1 Basic Checks

LEXX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LEXX has more shares outstanding
Compared to 5 years ago, LEXX has more shares outstanding
There is no outstanding debt for LEXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LEXX Yearly Shares OutstandingLEXX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
LEXX Yearly Total Debt VS Total AssetsLEXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

LEXX has an Altman-Z score of 776.29. This indicates that LEXX is financially healthy and has little risk of bankruptcy at the moment.
LEXX has a better Altman-Z score (776.29) than 100.00% of its industry peers.
There is no outstanding debt for LEXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 776.29
ROIC/WACCN/A
WACC8.51%
LEXX Yearly LT Debt VS Equity VS FCFLEXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

LEXX has a Current Ratio of 29.64. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LEXX (29.64) is better than 97.30% of its industry peers.
LEXX has a Quick Ratio of 29.64. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.
LEXX has a better Quick ratio (29.64) than 97.30% of its industry peers.
Industry RankSector Rank
Current Ratio 29.64
Quick Ratio 29.64
LEXX Yearly Current Assets VS Current LiabilitesLEXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.68% over the past year.
The Revenue has grown by 76.66% in the past year. This is a very strong growth!
Measured over the past years, LEXX shows a quite strong growth in Revenue. The Revenue has been growing by 16.11% on average per year.
EPS 1Y (TTM)43.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.08%
Revenue 1Y (TTM)76.66%
Revenue growth 3Y-13.61%
Revenue growth 5Y16.11%
Sales Q2Q%21.58%

3.2 Future

The Earnings Per Share is expected to decrease by -11.19% on average over the next years. This is quite bad
Based on estimates for the next years, LEXX will show a very strong growth in Revenue. The Revenue will grow by 221.49% on average per year.
EPS Next Y-21.96%
EPS Next 2Y-5.99%
EPS Next 3Y-11.19%
EPS Next 5YN/A
Revenue Next Year51.14%
Revenue Next 2Y41.17%
Revenue Next 3Y84.21%
Revenue Next 5Y221.49%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LEXX Yearly Revenue VS EstimatesLEXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
LEXX Yearly EPS VS EstimatesLEXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LEXX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LEXX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LEXX Price Earnings VS Forward Price EarningsLEXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEXX Per share dataLEXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

A cheap valuation may be justified as LEXX's earnings are expected to decrease with -11.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.99%
EPS Next 3Y-11.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LEXX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXARIA BIOSCIENCE CORP

NASDAQ:LEXX (2/21/2025, 8:00:02 PM)

After market: 1.4512 +0 (+0.08%)

1.45

+0.02 (+1.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-10 2025-01-10/dmh
Earnings (Next)04-07 2025-04-07
Inst Owners8.04%
Inst Owner Change-94.23%
Ins Owners7.81%
Ins Owner Change39.73%
Market Cap25.45M
Analysts82.5
Price Target9.18 (533.1%)
Short Float %3.77%
Short Ratio3.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.75%
Min EPS beat(2)-30.72%
Max EPS beat(2)-24.78%
EPS beat(4)1
Avg EPS beat(4)-9.42%
Min EPS beat(4)-30.72%
Max EPS beat(4)41.18%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)13.69%
Min Revenue beat(2)-52.94%
Max Revenue beat(2)80.31%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10%
PT rev (3m)-10%
EPS NQ rev (1m)-93.75%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-25.95%
EPS NY rev (3m)-41.03%
Revenue NQ rev (1m)-31.5%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)8.58%
Revenue NY rev (3m)-24.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 51.21
P/FCF N/A
P/OCF N/A
P/B 2.6
P/tB 2.75
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.03
BVpS0.56
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74.74%
ROE -74.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.45%
FCFM N/A
ROA(3y)-124.81%
ROA(5y)-108.73%
ROE(3y)-127.55%
ROE(5y)-113.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.01%
GM growth 5Y1.71%
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 231.33%
Cap/Sales 37.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 29.64
Quick Ratio 29.64
Altman-Z 776.29
F-Score5
WACC8.51%
ROIC/WACCN/A
Cap/Depr(3y)180.34%
Cap/Depr(5y)128.2%
Cap/Sales(3y)61.26%
Cap/Sales(5y)40.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.08%
EPS Next Y-21.96%
EPS Next 2Y-5.99%
EPS Next 3Y-11.19%
EPS Next 5YN/A
Revenue 1Y (TTM)76.66%
Revenue growth 3Y-13.61%
Revenue growth 5Y16.11%
Sales Q2Q%21.58%
Revenue Next Year51.14%
Revenue Next 2Y41.17%
Revenue Next 3Y84.21%
Revenue Next 5Y221.49%
EBIT growth 1Y-20.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-31.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.65%
OCF growth 3YN/A
OCF growth 5YN/A